Ilatreotide

C[C@@H](O)[C@H]1C(N[C@H](C(N[C@@H]([C@H](O)C)CO)=O)CSSC[C@H](NC([C@H](NC[C@]2(O)[C@@H](O)[C@H](O[C@@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](O)CO2)CC4=CC=CC=C4)=O)C(N[C@@H](CC5=CC=CC=C5)C(N[C@H](CC6=CNC7=CC=CC=C76)C(N[C@@H](CCCCN)C(N1)=O)=O)=O)=O)=O

[1]Drum, et al. Use of somatostatin analogs in myocardial perfusion imaging. Patent. WO2008143958 A1.|[2]Nelson-Piercy C, et al. Effect of a new oral somatostatin analog (SDZ CO 611) on gastric emptying, mouth to cecum transit time, and pancreatic and gut hormone release in normal male subjects. J Clin Endocrinol Metab. 1994 Feb;78 (2) :329-36.|[3]Albert R, et al. SDZ CO 611: a highly potent glycated analog of somatostatin with improved oral activity. Life Sci. 1993;53 (6) :517-25.